Skip to main content

Advertisement

Fig. 3 | Malaria Journal

Fig. 3

From: Efficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model

Fig. 3

Survival probability analysis of the treated mice after infection with Plasmodium berghei ANKA, and treated on day 8 post-infection (pi) with various dosages of the trioxaquine, artesunate, 4,7-dichloroquine, and quinine. The mice were monitored for 60 days post-treatment. The experimental animals were first infected with an inoculum of 0.2 ml of approximately 1 × 105 parasitized erythrocytes with P. berghei ANKA, treated with 25 and 12.5 mg/kg of the test drug on day 8 pi, twice a day for 3 days and their survival monitored for 60 days post-treatment. Quinine at 60 mg/kg, artesunate at 12.5 mg/kg, 4,7-dichloroquinoline at 12.5 mg/kg, and untreated control groups were included. Survival probability analysis using Kaplan–Meier software revealed that there was a significant reduction in mortality in trioxaquine-treated groups (p < 0.05) in comparison to the standards (quinine, artesunate, 4,7-dichloroquinoline). Apart from the trioxaquine treatment groups, all the other treatment groups, as well as the negative controls, had 100% mortality by day 16 pi

Back to article page